ICPT(Delisted)
Intercept PharmaceuticalsยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICPT
Intercept Pharmaceuticals, Inc.
A biopharmaceutical company focused on novel therapeutics to treat chronic liver disease
305 Madison Avenue, Morristown, NJ 07960
--
Intercept Pharmaceuticals, Inc., incorporated in Delaware on September 4, 2002, is a development-stage pharmaceutical company focused on the development and sale of novel therapies for chronic liver diseases using its proprietary bile acid chemistry. The company's products have therapeutic potential for the treatment of isolated, prevalent liver diseases, for which there are still limitations.
Company Financials
EPS
ICPT has released its 2023 Q2 earnings. EPS was reported at -0.14, versus the expected -0.51, beating expectations. The chart below visualizes how ICPT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICPT has released its 2023 Q3 earnings report, with revenue of 88.79M, reflecting a YoY change of 14.44%, and net profit of -2.79M, showing a YoY change of -101.04%. The Sankey diagram below clearly presents ICPT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
